Pharmafile Logo
Pharmafocus logo
Advanced Search

New Commercial Realities – Part 4 Key implications of this changing industry landscape for pharmaceutical commercial operations – governance

October 5, 2010
Sales and Marketing Kinapse, White paper

Faced with a changing healthcare environment and the prospect of diminishing commercial returns, the pharmaceutical industry has recognised that traditional …

Feature
White paper

Chris Brinsmead joins the Board of Kinapse

October 5, 2010
Kinapse

London, UKThe Board of Directors of Kinapse Ltd. is delighted to announce that Chris Brinsmead has agreed to become a …

News
Press release

GSK takes stake in biotech spin-out

October 5, 2010
Research and Development, Sales and Marketing Convergence, GlaxoSmithKline, funding

GlaxoSmithKline has taken a stake in a newly-launched biotech company in return for handing it two clinical compounds. The pharma …

News
Elan facility

Elan debuts manufacturing services business

October 5, 2010
Manufacturing and Production Elan

Irish pharmaceutical company Elan marked its official entry into the solid dose contract manufacturing sector today at the ongoing CPhI …

News

Recipharm buys Abbott plant to enter Spanish market

October 5, 2010
Manufacturing and Production Abbott, Recipharm, Solvay

Swedish contract development and manufacturing services company Recipharm has agreed to buy a facility in Parets del Valles, Spain, from …

News

Digital Pharma: Pfizer socialises pain campaign

October 5, 2010
Medical Communications Digital Pharma blog, Facebook, Flickr, Pfizer, Twitter, social media

Pfizer is campaigning for better care for people suffering from chronic pain and has turned to social media to galvanise …

News

Svend Andersen to lead Hospira in Europe

October 5, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Hospira, appointment, manufacturing and production, research and development, sales and marketing

US global specialty pharmaceutical company Hospira has appointed Svend Andersen to lead its operations in Europe with effect from 1 …

Appointment

Talking R&D: Evolving technical standards

October 5, 2010
Manufacturing and Production, Research and Development Talking R&D, eCTD, eCTD submissions

The European Union (EU) Module 1 specification works in parallel with the ICH eCTD Specification. It was first introduced in …

Feature

Sanofi makes hostile offer for Genzyme

October 4, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Genzyme, Sanofi-Aventis

Sanofi-Aventis’ courtship dance around Genzyme has turned more aggressive with an offer – made over the heads of Genzyme’s board …

News

Managing the Franchise

October 4, 2010
Sales and Marketing branding, marketing, product portfolio

Commercial managers who are responsible for a number of brands face a constant dilemma in choosing where across the franchise …

Feature

Mitsui boosts contract manufacturing business

October 4, 2010
Manufacturing and Production API, Arch Pharmalabs, India, Mitsui

Mitsui & Co has taken a 5% stake in Indian active pharmaceutical ingredients manufacturer Arch Pharmalabs in a $13 million …

News

Further expansion for Doctors.net.uk pharma team

October 4, 2010
Sales and Marketing Doctors.net.uk, GPs, communications, doctors, pharma marketing

 New hires to support and drive rapid growth  

News
Press release

GSK drops herpes vaccine

October 4, 2010
Research and Development, Sales and Marketing GlaxoSmithKline, Simplirix, herpes, sexual health

Poor phase III results have forced GlaxoSmithKline to halt development of its Simplirix vaccine for women with genital herpes. The …

News

David Gallagher to head up IPHA

October 4, 2010
Sales and Marketing IPHA, appointment, sales and marketing

Pfizer Healthcare Ireland’s managing director David Gallagher has been elected president of the Irish Pharmaceutical Healthcare Association (IPHA). David has …

Appointment

Talking R&D: US regulatory guidelines

October 4, 2010
Manufacturing and Production, Research and Development Talking R&D, eCTD submissions

Recent speculation surrounding current diabetes drugs and their long term effect on cardiovascular health has heads spinning in the pharmaceutical …

Feature

Zydus Nycomed’s API plant to start production soon

October 4, 2010
Manufacturing and Production API, India, Nycomed, Zydus Cadila

Nycomed has said that construction and validation of an active pharmaceutical ingredient manufacturing unit at its plant in Navi Mumbai, …

News

AZ-BMS diabetes drug impresses in phase III trials

October 1, 2010
Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes

AstraZeneca and Bristol Myers Squibb’s potential first-in-class diabetes drug dapagliflozin has shown strong results in a late stage trial. It …

News

FDA unveils new trial data rules

October 1, 2010
Research and Development FDA, clinical trials, pharmacovigilance

The FDA has clarified its rules on what safety information must be reported during clinical trials of investigational drugs and …

News

BMS poaches AZ’s head of global medical affairs

October 1, 2010
Research and Development, Sales and Marketing BMS, appointment, research and development, sales and marketing

Bristol-Myers Squibb has appointed Dr Rick Lones as executive medical director in the UK. He joins BMS from AstraZeneca, where …

Appointment

New digital agency Intensity launched

October 1, 2010
Medical Communications Creston, Intensity, OnMedica, Pan, Red Door

Medical communications group Creston has launched a new digital specialist agency called Intensity Digital. The start-up agency aims to serve …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026